

533,077

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date  
21 May 2004 (21.05.2004)

PCT

(10) International Publication Number  
**WO 2004/041280 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/4439**

University, Daehyeon-dong, Seodaemoon-ku, 120-750 Seoul (KR).

(21) International Application Number:

PCT/KR2003/002332

(74) Agent: DARAE PATENT FIRM; 10th Floor, KIPS, 647-9, Yeoksam-dong, Kangnam-ku, Seoul 135-980 (KR).

(22) International Filing Date:

3 November 2003 (03.11.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language:

Korean

(26) Publication Language:

English

(30) Priority Data:

10-2002-0067653

2 November 2002 (02.11.2002) KR  
10-2003-0075511 28 October 2003 (28.10.2003) KR

(84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant and

(72) Inventor: LEE, Kyung-Lim [KR/KR]; Division of Molecular Life Sciences, College of Pharmacy, Ewha Womans University, Deahyeon-dong, Seodaemoon-ku, 120-750 Seoul (KR).

**Published:**

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (for US only): LEE, Chul-Hee [KR/KR]; Otorhinolaryngology, Seoul National University Hospital, Yeongeon-dong, Jongro-ku, 110-744 Seoul (KR). CHOI, Seung-Hee [KR/KR]; Division of Molecular Life Sciences, College of Pharmacy, Ewha Womans

WO 2004/041280 A1

(54) Title: COMPOSITION FOR PREVENTING SECRETION OF IMMUNOGLOBULIN E-DEPENDENT HISTAMINE RELEASING FACTOR

(57) Abstract: The present invention relates to a composition for inhibiting the secretion of an immunoglobulin E (IgE)-dependent histamine-releasing factor, and pharmaceutical use thereof. The composition of the present invention contains a benzimidazolic compound having proton pump inhibitor activity, as an active ingredient. Furthermore, the composition of the present invention may contain at least one substance selected from the group consisting of fenotimine, oleic acid, catechin, scopadulciol, pentagalloyl glucose, bufalinin, and macrolide antibiotic baflomycin and concanamycin, all having proton pump inhibitor activity, as an additional active ingredient or a single active ingredient. The composition of the present invention can be advantageously used as a pharmaceutical composition for the prevention and treatment of various allergic diseases and malaria, which are caused by the IgE-dependent histamine-releasing factor.

BEST AVAILABLE COPY

**COMPOSITION FOR PREVENTING SECRETION OF  
IMMUNOGLOBULIN E-DEPENDENT HISTAMINE RELEASING FACTOR**

**Technical Field**

5       The present invention relates to a composition for inhibiting the secretion of an immunoglobulin E (IgE)-dependent histamine-releasing factor (hereinafter, referred to as "HRF"), and pharmaceutical use thereof.

**Background Art**

10       HRF is known to perform an important role in late phase allergic reaction (hereinafter, referred to as "LPR"), and to stimulate a basophil to induce histamine secretion so as to mediate various allergic diseases (McDonald et al., 1995).

Also, HRF is known to be a kind of tumor protein that binds to Artemisinin as an anti-malaria agent in malaria mosquitoes (Bhisutthibhan, 1998).

15       Allergic diseases, which are caused by HRF, include anaphylaxis, asthma, urticaria, allergic rhinitis, allergic bronchiectasis, hay fever, atopic dermatitis and the like. Particularly, as the probability of exposure to various allergens rapidly increases due to environmental contamination, the allergic diseases show a tendency to further increase.

20       HRF is hydrophilic in nature and a cytoplasmic protein having no signal peptide that is generally contained in proteins which are released extracellularly. However, a study result showing that HRF is also detected extracellularly was reported (McDonald et al., 1995), and HRF was found to stimulate an IgE-sensitized basophil extracellularly to induce histamine secretion.

25       Accordingly, there have been efforts in an attempt to establish a mechanism

on the extracellular secretion of the cytoplasmic protein HRF and to develop a substance capable of inhibiting this process, and thus, to prevent and inhibit various diseases caused by HRF.

Molecules that were known, up to now, to have no signal peptide while being detected extracellularly, like HRF, include a basic fibroblast growth factor (FGF-2), a plasminogen activator inhibitor 2 (PAI-2), a carbohydrate-binding protein 30 (CBP 30) and the like.

Although the secretion pathway of such molecules was not yet clearly established, a study result indicating that a Na/K-ATPase pump can be a potential FGF-2 release pathway was recently reported (Florkiewicz RZ, 1998).

On the basis of this fact, the present inventors have established the secretion pathway of HRF on the assumption that HRF can also be secreted via the pump, and invented a composition capable of inhibiting HRF secretion.

15

### Disclosure of Invention

Accordingly, an object of the present invention is to provide a composition for inhibiting HRF secretion and, pharmaceutical use thereof.

The present invention provides a composition for inhibiting the secretion of an IgE-dependent histamine-releasing factor, and pharmaceutical use thereof.

20 The composition of the present invention contains a benzimidazolic compound with proton pump inhibiting activity, as an active ingredient.


As used herein, the term "proton pump" means  $H^+-K^+$  ATPase, a membrane protein, which actively transports a hydrogen ion ( $H^+$ ) to the outside of cytoplasm, in a direction opposite to concentration gradient.

25 The benzimidazolic compound, which is used in the inventive composition,

is a lipid-soluble weak base consisting of a benzimidazole ring, a pyridine ring and a methylsulfinyl group located between them, and has a structure represented by the following formula (1):



5 (1)



which may be the same or different, each independently represents hydrogen, methoxy, or difluoromethoxy;  $\text{R}^3$  represents hydrogen or sodium; and  $\text{R}^4$ ,  $\text{R}^5$  and  $\text{R}^6$ , which may be the same or different, each independently represents hydrogen, methyl, 10 methoxy, methoxypropoxy, or trifluoroethoxy.

The benzimidazolic compound used in the present invention may be preferably one or more selected from the group consisting of omeprazole, lansoprazole, pantoprazole and rabeprazole.

In addition to such substances, the benzimidazolic compound used in the 15 present invention may also be derivatives and isomers of such substances, and preferably hydroxy-omeprazole, hydroxy-lansoprazole, carboxylic acid derivatives of omeprazole, desmethyl-pantoprazole, esomeprazole, or the like.

The benzimidazolic compound used in the present invention inhibits a proton pump so as to inhibit the extracellular secretion of HRF. This is because the 20 proton pump is involved in the secretion process of HRF.

Thus, the use of the inventive composition can inhibit HRF secretion

induced by allergy-causing substances resulting in an increase in histamine concentration.

Particularly, the composition of the present invention inhibits HRF secretion caused by C48/80 so as to reduce HRF or histamine concentration in blood, resulting  
5 in a remarkable reduction in the probability of death from the systemic anaphylaxis reaction caused by C48/80.

The composition of the present invention reduces the amount of HRF and histamine in blood, such that the probability of death from the systemic anaphylaxis reaction caused by allergy-causing substances is remarkably reduced and symptoms  
10 of allergic rhinitis are effectively mitigated.

Furthermore, the composition of the present invention has the effect of reducing the expression of symptoms and histological change of allergic rhinitis in a mouse model with allergic rhinitis.

Thus, the composition of the present invention can be advantageously used  
15 as a pharmaceutical composition for the prevention and treatment of various allergic diseases caused by HRF, i.e., asthma diseases, including asthma from foods or drugs, such as aspirin, allergic asthma, urticaria, anaphylaxis, allergic rhinitis, allergic bronchiectasis, hay fever, atopic dermatitis and malaria.

The composition of the present invention may contain a substance with the  
20 same or similar function to the above-mentioned substances, as an additional active ingredient or a single active ingredient. Specifically, the composition of the present invention may contain, as an additional active ingredient or a single active ingredient, at least one substance selected from the group consisting of fenoctimine, oleic acid, catechin, scopadulciol, pentagalloyl glucose, bufalin, and macrolide antibiotic  
25 bafilomycin and concanamycin, which are known to have proton pump inhibition

activity.

If necessary, the composition of the present invention may additionally contain a substance with a different function from the above-mentioned substances, as an active ingredient.

5 In addition to such active ingredients, the composition of the present invention may contain pharmaceutically suitable and physiologically acceptable adjuvants, such as solubilizers, solvents, disintegrants, sweeteners, binders, coating agents, swelling agents, lubricants, or flavoring agents.

For administration, the composition of the present invention may be  
10 formulated with at least one pharmaceutically acceptable carrier in addition to the above-mentioned active ingredients.

Examples of the pharmaceutically acceptable carrier, which can be used in the present invention, include saline solution, dextrose solution, maltodextrin solution, glycerol, ethanol and a mixture thereof. If necessary, the inventive  
15 composition may contain other conventional additives, such as antioxidants, buffer solution and bacteriostatic agents. Moreover, the inventive composition may be formulated into an injectable liquid, such as water solution, suspension and emulsion, pills, capsules, granules or tablets, by the addition of diluents, dispersants, surfactants, binders and lubricants. Furthermore, it can be preferably formulated depending on  
20 diseases or its components, using a method described in Remington's Pharmaceutical Science (latest edition), Mack Publishing Company, Easton PA.

The formulated form of the inventive composition may be granules, powders, coated pills, tablets, capsules, suppositories, syrup, juice, suspension, emulsion, drops, injectable liquids, or a sustained release preparation of the active compounds.

25 The composition of the present invention can be administered by various

routes, including oral, intravenous, intraarterial, intraabdominal, intramuscular, intrasternal, subcutaneous, intradermal, intranasal, topical, rectal, and intradermal routes, in a conventional manner.

When the composition of the present invention contains pantoprazole, it is  
5 preferably administered at a dosage of 10 mg/kg body weight for a rat or mouse, and  
at a dosage of 100 µg-1 mg per kg body weight for a man. The dosage of the  
inventive composition can vary depending on various factors, including the kind of  
diseases, the severity of diseases, the kind and content of the active ingredients and  
other components in the composition, the kind of a formulation, the age, body weight,  
10 general health condition, sex and diet of a patient, the administration time,  
administration route and percent secretion of the composition, therapeutic period,  
and a drug that is used simultaneously with the composition.  
15

The composition of the present invention is a drug that has been previously  
used for the treatment of gastric ulcer, duodenal ulcer, Zollinger-Ellison syndrome  
and reflux esophagitis and whose safety was established. Thus, it has no particular  
side effects on a living body.

The composition of the present invention can be used alone or in  
combination with diet therapy, chemical therapy, and methods utilizing an agent for  
regulating biological reaction.

20

#### **Brief Description of Drawings**

FIG 1 shows that HRF is secreted into serum of a variety of allergic patients;

FIG 2 shows that HRF is secreted extracellularly by allergy-causing  
substances;

25 FIG 3 shows that a composition of the present invention inhibits HRF

secretion, which is increased by allergy-causing substances *in vitro*;

FIG. 4 shown that a composition of the present invention reduces blood HRF concentration, which is increased by allergy-causing substances *in vivo*;

FIG. 5 shows that a composition of the present invention inhibits the expression of symptoms of allergic rhinitis in an allergic mouse model; and

FIG. 6 shows that a composition of the present invention inhibits the increase of eosinophil number in a mouse with allergic rhinitis.

#### **Best Mode for Carrying Out the Invention**

10 The present invention will hereinafter be described in further detail by examples. It will, however, be obvious to a person skilled in the art that the examples are given for illustrative purpose only, and the present invention is not limited to or by the examples.

15 Example 1: Effect of inventive composition on inhibition of HRF secretion

To examine the effect of the inventive composition on the inhibition of HRF secretion, the correlation between HRF secretion, allergic symptoms and allergy-causing substances was established and then the effect of the inventive composition on HRF secretion was examined.

20 1) Examination of correlation between HRF secretion, allergic symptoms and allergy-causing substances

The correlation between HRF secretion, allergic symptoms and allergy-causing substances was examined as follows.

25 1-1) In order to examine if the secretion of HRF in various allergic symptoms is increased, a variety of allergic patients, including patients showing

asthma response to aspirin administration, patients showing asthma response to other allergens than aspirin, patients with allergic asthma, patients showing food-dependent exercise-induced anaphylaxis, and patients with urticaria, were selected and examined for an increase in HRF secretion.

5       The patients showing asthma response to aspirin administration were divided into two groups consisting of a dual response patient group showing asthma response both just and some time after aspirin administration, and an early response patient group showing asthma response only just after aspirin administration.

10      To examine if HRF is present in blood, a small amount of serum was collected from each patient, and in the case of the patients showing allergic response to other allergens than aspirin, serum was collected in a state where they were not exposed to the allergens. As a negative control group, the serum of normal persons who show no allergic response was also collected.

15      The serum of each group was mixed with the same amount of 4 x sample buffer solution. At this time, the ratio of glycerol in the sample buffer solution was 50% such that the attraction phenomenon of bands upon electrophoresis is prevented. The sample mixture was denatured in boiling water for 3 minutes, cooled for a short time, centrifuged at 12,000 rpm for 5 minutes, and then only the supernatant was collected.

20      The sample prepared as described above was subjected to Western blotting analysis in the same manner as the part 1-2) of Example 1, and the results are shown FIG 1.

25      As shown in FIG 1, a high concentration of HRF was detected in all the serum of the patients with dual response to aspirin administration (a), the patients with early response to aspirin administration (b), the patients showing asthma

response to other allergens than aspirin (c), the patients with allergic asthma (d), the patients with food-dependent exercise-induced anaphylaxis (e), and the patients with urticaria (f). On the other hand, in the serum of the normal person (g), HRF was no substantially detected.

5 Thus, since HRF is detected in a variety of allergic patients, it can be found that HRF secretion performs an important role in allergic reaction.

#### 1-2) Increase of HRF secretion by C48/80

In order to examine the effect of allergy-causing substances on HRF secretion, C48/80 (compound 48/80, Sigma) as a typical allergy-causing substance 10 was selected and subjected to the following test.

As a cell model for HRF secretion, a U-937 cell was selected and cultured in a RMPI 1640 medium containing 1% L-glutamine, 100 U/ml penicillin, 100 U/ml streptomycin and 10% fetal bovine serum, at 37 °C and 5% CO<sub>2</sub>.

The culture medium of the U-937 cell was centrifuged at 1,000 rpm for 3 15 minutes, and the cell was collected, washed one time with a phosphate buffered saline (PBS; 200 mg/l potassium chloride, 200 mg/l potassium dihydrogen phosphate, 8 g/l sodium chloride, 1.15 g/l sodium phosphate dibasic), and centrifuged again at 1,000 rpm for 3 minutes, and the cells were collected.

The collected cells were added with a RPMI medium containing only 1% L- 20 glutamine, and shaken such that the precipitated cells were well mixed with the medium. Then, some of the solution was taken and dyed with tryphan blue (Gibco BRL), and the number of living cells was counted. The cells were plated at 10<sup>6</sup> cells/well in a 6-well plate, and left to stand in a starvation state at 37 °C and 5% CO<sub>2</sub> for 5 hours. Upon the end of the cell starvation, each well of the 6-well plate 25 was treated with C48/80 (Sigma) at concentrations of 0 µg/ml, 2 µg/ml, 4 µg/ml, 6

$\mu\text{g}/\text{ml}$ , 8  $\mu\text{g}/\text{ml}$  and 10  $\mu\text{g}/\text{ml}$  for 30 minutes, and the cells were separated from the supernatant.

The supernatant was added with a protease inhibitor cocktail consisting of 100 mM PMSF, 1 mg/ml aprotinin, 1 M benzamidine and 10 mg/ml leupeptin, and 5 centrifuged at 4 °C and 12,000 rpm for several hours with a concentrator (Centricon, Sartorius) using the centrifugal force so as to concentrate to 1/100 of the original volume.

The concentrate was added with 4 x sample buffer (1 M Tris (pH 6.8), 10% SDS, 100% glycerol, several drops of bromophenol blue, a small amount of  $\beta$ -mercaptoethanol, and deionized water), denatured in boiling water for 10 minutes, 10 and then immediately, moved onto ice so as to prevent the denatured protein from being returned to the original state.

The sample obtained as described above was electrophoresed on 15% SDS-PAGE gel, transferred to a nitrocellulose membrane and then analyzed by Western 15 blotting.

In the Western blotting analysis, a 4,000-fold dilution of a polyclonal anti-HRF antibody in Tris buffered saline with 0.05% tween 20 was used as a primary antibody, and a 10,000-fold dilution of a goat anti-rabbit IgG-HRP in Tris buffered saline with 0.05% Tween 20 was used as a secondary antibody. Then, the protein 20 bands of the washed membrane were analyzed using an image analyzer system, and the results are shown in FIG. 2.

As shown in FIG. 2, the histamine-releasing substance C48/80 caused the increase of HRF secretion in a concentration-dependent manner. Due to this characteristic, C48/80 was used as an agent for increasing HRF secretion in a 25 subsequent Example.

## 2) Preparation of inventive composition

The composition of the present invention was prepared by dissolving omeprazole (Sigma) in ethanol at a concentration of 13 mM.

When treating cells with the composition of the present invention, the  
5 omeprazole was used at final concentrations of 10 µM and 100 µM.

## 3) Effect of inventive composition on inhibition of HRF secretion

The effect of the composition of the present invention on the inhibition of HRF secretion was examined as follows.

In the same manner as the part 1-2) of Example 1, cells were plated on a 6-well plate, and left to stand in a starvation state for 5 hours. Then, an untreated group, a group treated with 10 µg/ml of C48/80, a group treated with each of 10 µM and 100 µM of omeprazole, a group treated with 10 µM of omeprazole and 10 µg/ml of C48/80, and a group treated with 100 µM of omeprazole and 10 µg/ml of C48/80,  
10 were provided, and the cells of each group was isolated from the supernatant and  
15 collected.

The collected cells were washed one time with a phosphate buffered saline, precipitated by centrifugation at 12,000 rpm for 10 minutes, resuspended in a cell lysis buffer (20 mM Tris (pH 7.4), 150 mM sodium chloride, 5 mM EDTA, 0.5% deoxycholate, 2 mM EGTA, 1% NP40, protease cocktail), and vortexed.

20 The cell mixture was kept on ice with 2 or 3 times vortexing, and then centrifuged at 12,000 rpm for 10 minutes, and the supernatant was collected. A portion of the supernatant was taken and quantified for protein by a Bradford assay. Then, the supernatant containing the same amount of protein was added with a 4 x sample buffer, boiled for 10 minutes and cooled, thereby giving a sample to be  
25 electrophoresed. Western blotting analysis was performed on the sample in the

same manner as the part 1-2) of Example 1, and the results are shown in FIG. 3.

As shown in FIG. 3, the composition of the present invention effectively inhibited the secretion of HRF, which is increased by C48/80. Thus, from the fact that the secretion of HRF is inhibited by the proton pump inhibitor, it can be found  
5 that the proton pump is involved in the secretion of HRF.

As a result, the inventive composition containing the proton pump inhibitor as an active ingredient is useful for the prevention and treatment of various allergy symptoms caused by HRF.

10           Example 2: Effect of inventive composition on anaphylaxis inhibition

1) Preparation of the composition of the present invention

Pantoprazole (PANTOLOC, Pacific Pharmaceuticals) was dissolved in a phosphate buffered saline at a concentration of 4.8 mM to prepare the composition of the present invention.

15           When administering the inventive composition to animals, the pantoprazole was used at the amount of 10 mg/kg body weight.

2) Effect of inventive composition on anaphylaxis inhibition

The effect of the composition of the present invention on anaphylaxis inhibition was examined as follows.

20           SD mice weighing 200-220 g were divided into three groups consisting of a negative control group, a positive control group and a test group, each group consisting of eight animals. In the negative and positive control groups, a phosphate buffered saline was administered by injection through the tail vein, and in the test group, the inventive composition was administered by injection through the  
25 tail vein in such a manner that the amount of use of pantoprazole was 10 mg/kg body

weight.

30 minutes after this pretreatment, the negative control group was injected with a phosphate buffer saline through the tail vein, the positive control group and the test group were injected with 10 mg/kg of C48/80 through the tail vein. After 5 the injection, the number of individuals died of anaphylaxis reaction caused by C48/80 was observed. The standard of death and survival was determined by whether or not the animals survive for one hour after C48/80 administration. The result of mortality for each group is given in Table 1 below.

Table 1:

| Groups                 | Pretreatment<br>(-30 minutes)    | Anaphylaxis reaction-causing substance | Mortality<br>(number of dead individuals / number of total individuals) |
|------------------------|----------------------------------|--|---|
| Negative control group | Phosphate buffered saline        | Phosphate buffered saline              | 0/8   |
| Positive control group |                                  | C48/80 (10 mg/kg)                      | 7/8   |
| Test group             | Inventive composition (10 mg/kg) |  | 4/8   |

10

As shown in Table 1, it can be found that the composition of the present invention remarkably reduces anaphylaxis reaction in the animals. This result coincides with the result of Example 1 showing that the inventive composition inhibits the secretion of HRF from cells.

15 As a result, the composition of the present invention is useful for the prevention and treatment of diseases caused by a hypersensitive immune response which can be induced by HRF.

### 3) Effect of inventive composition on blood histamine concentration

In order to examine if the effect of the inventive composition on anaphylaxis

inhibition, as indicated the part 2) of Example 2, is attributed to the reduction of blood histamine concentration, the following test was performed.

- In the case of the dead mice among the mice used in the part 2 of Example 2, a small amount of blood was collected from the heart just before or just after death.
- 5 In the case of the survived mice, a small amount of blood was collected after anesthesia with ether.

The collected blood was left to stand at 4 °C overnight to coagulate blood-corpuscles, and centrifuged at 3,000 rpm for 10 minutes, and the serum was isolated. A portion of the serum was taken, 10 to 300-fold diluted in deionized water, and 10 analyzed for blood histamine concentration using a histamine analyzer, and the results are given in Table 2 below.

Table 2:

| Groups                 | Pretreatment                     | Blood histamine concentration<br>(average; ng/ml) |
|------------------------|----------------------------------|---|
| Negative control group |                                  | Not measurable*                                   |
| Positive control group | Phosphate buffered saline        | 2646.47   |
| Test group             | Inventive composition (10 mg/kg) | 301.8   |

\*not measurable: concentration was lower than a measurable range.

15 As shown in Table 2, in the blood of the test group pretreated with the inventive composition, the amount of histamine release was at least 80% lower than the positive control group.

As a result, the inventive composition has the effect of reducing blood histamine level and thus is useful for the prevention and treatment of anaphylaxis 20 reaction.

#### 4) Effect of inventive composition on blood HRF concentration

In order to examine if the effect of the inventive composition on the reduction of blood histamine concentration, as indicated in the part 2) of Example 2, is attributed to the reduction of HRF secretion, the following test was conducted.

The serum of each group obtained in the part 3) of Example 2 was mixed  
5 with the same amount of 4 x sample buffer solution. At this time, the ratio of glycerol in the used sample buffer solution was 50% such that the attraction phenomenon of bands upon electrophoresis is prevented. The sample mixture was denatured in boiling water for 3 minutes, cooled on ice for a short time, and centrifuged at 12,000 rpm for 5 minutes, and only the supernatant was collected.

10 In the same manner as the part 1-2) of Example 1, Western blotting analysis was conducted for the sample prepared as described above, and the results are shown in FIG. 4.

As shown in FIG. 4, the band of HRF was obviously detected in most of the blood of the animals that were not pretreated with the inventive composition and thus  
15 died of anaphylaxis reaction.

On the other hand, the band of HRF was not substantially detected in the blood of the group that was pretreated with the inventive composition and thus survived.

As a result, it can be found that HRF plays an important role in anaphylaxis  
20 reaction caused by C48/80, and the composition of the present invention can reduce blood HRF concentration and thus blood histamine level, thereby inhibiting anaphylaxis reaction.

Example 3: Effect of inventive composition on inhibition of allergic rhinitis

25 1) Preparation of inventive composition

When treating animals with the inventive composition, the composition was dissolved in a phosphate buffered saline such that pantoprazole is applied at the amounts of 10 mg/kg and 100 mg/kg for two test groups, respectively.

2) Test method

5        3-week-old BALBc male mice weighing 15-25 g were divided into four groups each comprising 6 or 7 animals, and then bred in a specific pathogen-free (SPF) environment for 35 days.

In order to induce allergic rhinitis, 10 µg of ovalbumin (grade V, Sigma Chemical Co., Phillipsburg, NY) and 1 mg of aluminum hydroxide ( $\text{Al(OH)}_3$ ) gel 10 were mixed with 0.3 ml phosphate buffered saline for at least 30 minutes to prepare an ovalbumin mixture.

0.1 ml of the mixture was injected into the abdominal cavity of the mice, and each at 5, 14 and 21 days later, injected once more into the abdominal cavity. At one week after the final injection into the abdominal cavity (28 days later), 30 µl 15 phosphate buffered saline or a mixture of 100 µg ovalbumin with 30 µl phosphate buffered saline was administered into the nasal cavity using a micropipette. At 30 minutes before the administration into the nasal cavity, a phosphate buffered saline and 10 mg/kg and 100 mg/kg of pantoprazole were administered into the abdominal cavity of control groups and two test groups, respectively, and the effect of the 20 inventive composition on the inhibition of allergic rhinitis was examined.

The administration of ovalalbumin into the nasal cavity and the pretreatment with the drugs before this administration were performed for 7 days, one time a day, and the next day after the administration for 7 days, the mice of all the groups was euthanized by inhalation with carbonic acid gas. The test procedure as described 25 above is summarized in Table 3 below.

Table 3:

| Groups                 |        | Systemic sensitization   |                  |                  |                  |   |  | Euthanasia |
|------------------------|--------|--|------------------|------------------|------------------|---|--|------------|
|                        | Number | 1 day  | 5 days           | 14 days          | 21 days          | 30 minutes before causing rhinitis                          | 28-24 days   | 35 days    |
| Negative control group | 6      | OVA<br>+<br>Alum   | OVA<br>+<br>Alum | OVA<br>+<br>Alum | OVA<br>+<br>Alum | Phosphate buffered saline                                   | Phosphate buffered saline  |            |
| Positive control group | 6      |  |                  |                  |                  | 10 mg/kg of inventive composition                           | OVA  |            |
| Test group I           | 7      |  |                  |                  |                  | 100 mg/kg of inventive composition                          |  |            |
| Test group II          | 7      |  |                  |                  |                  |   |  |            |
| Remarks                |        | Mixture of 10 µg OVA and 1 mg Alum was dissolved 300 µl phosphate buffered saline and administered into abdominal cavity |                  |                  |                  | Pretreatment before administration of OVA into nasal cavity | Phosphate or mixture of 100 µg and 30 µl phosphate buffered saline |            |

(OVA: ovalbumin; and Alum:  $\text{Al}(\text{OH})_3$ )

5           3) Effect of inventive composition on inhibition of symptoms of allergic rhinitis

The effect of the inventive composition on the inhibition of symptoms of allergic rhinitis was examined as follows:

The induction of allergic rhinitis in the nasal cavity was conducted in the 10 same manner as the part 2) of this Example. Then, in each mouse, the number of expression of characteristic symptoms of allergic rhinitis, i.e., the number of expression of symptoms, such as sneezing and the action of scratching the nose, was measured for 15 minutes after a given period, and their sum was recorded as a

symptom score. The symptom score was recorded as the mean of scores measured by two observers, and scores having at least 30% difference between the two observers were excluded. The symptom score for each group is shown in Table 4 and FIG. 5.

5 Table 4:

|               |                        | Negative control group | Positive control group | Group treated with inventive composition (10 mg/kg) | Group treated with inventive composition (100 mg/kg) |
|---------------|------------------------|------------------------|------------------------|---|--|
| Symptom score | Mean                   | 31.38                  | 65.00                  | 27.29   | 48.00  |
|               | Standard deviation     | 20.84                  | 33.15                  | 28.49   | 17.42  |
| p-value       | Negative control group | -                      | 0.078                  | 0.391   | 0.1  |
|               | Positive control group | -                      | -                      | 0.046   | 0.317  |

As shown in Table 4 and FIG. 5, it was found that in the groups treated with the inventive composition, symptoms of allergic rhinitis were remarkably reduced as compared to the positive control group.

10 As a result, it can be found that the inventive composition can effectively reduce allergic diseases, including allergic rhinitis and hay fever.

#### 4) Histological examination

The effect of the inventive composition on the increase of eosinophil number that is the histological characteristic of allergic diseases was examined as follows.

15 The head of the mice enthanized in the part 2) of this Example 2 was separated and immobilized in 10% formalin solution for 24 hours. Then, the skin was removed from the mouse's head and immersed in decalcifier B (Accra Lab, Swedesboro, NJ) for 24 hours. The nasal tissue was embedded in paraffin and then a coronal section with a 5  $\mu\text{m}$  thickness was collected.

20 This section was dyed with haematoxyloin and eosin, and then, a tissue

showing two teeth in the coronal section of the mouse nasal cavity was selected under an optical microscope and measured for eosinophil number under a mucosa in the anterior portion of the inferior turbinate at 400x magnifications. The measured results were statistically analyzed by the Mann-Whitney U-test, using SPSS for 5 Windows version 10 (SPSS Inc., Chicago), and were determined to be statistically significant at  $p < 0.05$ . The results are shown in Table 5 and FIG. 6.

Table 5:

|               |                        | Negative control group | Positive control group | Group administered with inventive composition (10 mg/kg) | Group administered with inventive composition (100 mg/kg) |
|---------------|------------------------|------------------------|------------------------|--|---|
| Symptom score | Mean                   | 1.33                   | 290.00                 | 5.57   | 4.29  |
|               | Standard deviation     | 2.34                   | 73.63                  | 13.00  | 4.99  |
| p-value       | Negative control group | -                      | 0.004                  | 0.703  | 0.366   |
|               | Positive control group | -                      | -                      | 0.003  | 0.003   |

As shown in Table 5 and FIG. 6, the groups administered with the 10 composition of the present invention showed a very lower eosinophil number than the positive control group.

As a result, it can be found that the composition of the present invention can effectively inhibit allergic diseases, including allergic rhinitis and hay fever.

#### 15 Industrial Applicability

As described above, the composition of the present invention has the effect of inhibiting HRF secretion induced by allergy-causing substances.

Furthermore, the composition of the present invention has the effect of reducing the amount of HRF and histamine in blood, so as to remarkably reduce the



probability of death from systemic anaphylaxis reaction induced by the allergy-causing substances and to mitigate symptoms of allergic rhinitis.

Accordingly, the composition of the present invention can be advantageously used as a pharmaceutical composition for the prevention and treatment of various 5 allergic diseases caused by HRF, i.e., asthma diseases, including asthma induced by foods or drugs (e.g., aspirin), allergic asthma, urticaria, anaphylaxis, allergic rhinitis, allergic bronchiectasis, hay fever, atopic dermatitis and malaria.

**What Is Claimed Is:**

1. A composition for inhibiting the secretion of IgE-dependent histamine-releasing factor (HRF), which contains a benzimidazolic compound having proton pump inhibitor activity, as an active ingredient.

2. The composition of Claim 1, wherein the benzimidazolic compound is a lipid-soluble weak base consisting of a benzimidazole ring, a pyridine ring and a methylsulfinyl group located between them, and has a structure represented by the following formula:



wherein Het<sup>1</sup> is ; Het<sup>2</sup> is ; R<sup>1</sup> and R<sup>2</sup> which may be the same or different, each independently represents hydrogen, methoxy, or difluoromethoxy; R<sup>3</sup> represents hydrogen or sodium; and R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup>, which may be the same or different, each independently represents hydrogen, methyl, methoxy, methoxypropoxy, or trifluoroethoxy.

3. The composition of Claim 2, wherein the benzimidazolic compound is one or more selected from the group consisting of omeprazole, lansoprazole, pantoprazole, rabeprazole, and derivatives and isomers thereof.

4. The composition of Claim 3, which additionally contains at least one substance selected from the group consisting of fenoctimine, oleic acid, catechin, scopadulciol, pentagalloyl glucose, bufalin, and macrolide antibiotic bafilomycin and concanamycin, which all have proton pump inhibitor activity.

5

5. The composition of any of Claims 1 to 4, which is used for the prevention and treatment of various allergic diseases caused by HRF, including asthma, urticaria, anaphylaxis, allergic rhinitis, allergic bronchiectasis, hay fever, atopic dermatitis and malaria.

10

6. The composition of Claim 5, which is used for the prevention and treatment of asthma, urticaria, allergic bronchiectasis, and atopic dermatitis.

15

7. The composition of Claim 5, which is used for the prevention and treatment of anaphylaxis, allergic rhinitis, and hay fever.

8. The composition of Claim 5, which is used for the prevention and treatment of malaria.

20

9. A composition for inhibiting the secretion of HRF, which contains, as a single active ingredient, at least one substance selected from the group consisting of fenoctimine, oleic acid, catechin, scopadulciol, pentagalloyl glucose, bufalin, and macrolide antibiotic bafilomycin and concanamycin, which all have proton pump inhibitor activity.

25

10. The composition of Claim 9, which is used for the prevention and treatment of various allergic diseases caused by HRF, including asthma, urticaria, anaphylaxis, allergic rhinitis, allergic bronchiectasis, hay fever, atopic dermatitis and malaria.

5


11. The composition of Claim 10, which is used for the prevention and treatment of asthma, urticaria, allergic bronchiectasis, and atopic dermatitis.

12. The composition of Claim 10, which is used for the prevention and  
10 treatment of anaphylaxis, allergic rhinitis, and hay fever.


13. The composition of Claim 10, which is used for the prevention and treatment of malaria.

## [DRAWING]


[FIG. 1]



[FIG. 2]




[FIG. 3]




C:control  
 1: C48/80 10  $\mu\text{g/ml}$   
 2: omeprazole 10  $\mu\text{M}$   
 3: omeprazole 100  $\mu\text{M}$   
 4: omeprazole 10  $\mu\text{M}$  + C48/80 10  $\mu\text{g/ml}$   
 5: omeprazole 100  $\mu\text{M}$  + C48/80 10  $\mu\text{g/ml}$


[FIG. 4]



[FIG. 5]



[FIG. 6]



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/KR2003/002332

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC7 A61K 31/4439

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**Minimum documentation searched (classification system followed by classification symbols)  
IPC7 A61KDocumentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
Korean patents and applications for inventions since 1975: IPC as aboveElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
CA on CD, STN online, PubMed**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category* | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|-----------|--|-----------------------|
| Y         | HAMAGUCHI T., TAKAHASHI A., MANAKA A., SATO M., OSADA H., 'TU-572, a potent and selective CD45 inhibitor, suppresses IgE-mediated anaphylaxis and murine contact hypersensitivity reactions', Int. Arch. Allergy Immunol., 2001, Vol. 126, No. 4, 318-324 abstract; claim 1-3, 5, 6  | 1-3, 5, 6             |
| Y         | OHMORI Y., ITO M., KISHI M., MIZUTANI H., KATADA T., KONISHI H., 'Antiallergic constituents from oolong tea stem', Biol. Pharm. Bull., 1995, Vol. 18, No. 5, 683-686 abstract; claim 9-12  | 9-12                  |
| A         | US 6369091 B1 (Avanir Pharmaceuticals) 09 Apr. 2002 (2002-04-09) claim 1-9; claim 1-8  | 1-8                   |
| A         | SUSAN M. MACDONALD, JAMAREE BHISUTTHIBHAN, THERESA A. SHAPIRO, STEPHEN J. ROGERSON, TERRIE E. TAYLOR, MADALITSO TEMBO, JACQUELINE M. LANGDON, STEVEN R. MESHNICK, 'Immune mimicry in malaria: Plasmodium falciparum secretes a functional histamine-releasing factor homolog in vitro and in vivo', Proceeding of the National Academy of Sciences of the United States of America, 2001, Vol. 98, No. 19, 10829-10832 the whole document; claim 8, 13 | 8, 13                 |

 Further documents are listed in the continuation of Box C. See patent family annex.

\* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

27 JANUARY 2004 (27.01.2004)

Date of mailing of the international search report

28 JANUARY 2004 (28.01.2004)

Name and mailing address of the ISA/KR



Korean Intellectual Property Office  
920 Dunsan-dong, Seo-gu, Daejeon 302-701,  
Republic of Korea

Facsimile No. 82-42-472-7140

Authorized officer

LEE, HYUN SONG

Telephone No. 82-42-481-5606



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR2003/002332

| C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT |  |                       |
|---|--|-----------------------|
| Category*   | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
| A   | PASMANSG., AALBERS M., VAN DER VEEN MJ., KNOL EF., VAN DER ZEE JS., JANSEN HM., AALBERSE RC., 'Reactivity to IgE-dependent histamine-releasing activity in asthma or rhinitis', Am. J. Respir. Crit. Care Med., 1996, Vol. 154(2 pt 1), 318-323 abstract; claim 5-7, 10-12 | 5-7, 10-12            |
| A   | COREY JP., 'Advances in the pharmacotherapy of allergic rhinitis: second-generation H1-receptor antagonists', Otolaryngol Head Neck Surg., 1993, Vol 109(3 Pt 2), 584-592 abstract; claim 9, 10  | 9, 10                 |
| A   | NISHIMURA N., ITO K., TOMIOKA H., YOSHIDA S., 'Inhibition of chemical mediator release from human leukocytes and lung in vitro by a novel antiallergic agent, KB-2413', Immunopharmacol. Immunotoxicol., 1997, Vol. 9, No. 5, 511-521 abstract; claim 2-13                 | 2-13                  |
| A   | CHAND N., PILLAR J., DIAMANTIS W., SOFIA RD., 'Inhibition of IgE-mediated allergic histamine release from rat peritoneal mast cells by azelastine and selected antiallergic drugs', Agents Actions, 1985, Vol. 16, No. 5, 318-322 abstract; claim 1-13                     | 1-13                  |

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International application No.

PCT/KR2003/002332

| Patent document cited in search report | Publication date | Patent family member(s)  | Publication date   |
|--|------------------|--|--|
| US6369091B1                            | 09.04.02         | ZA0007754A<br>ZA0007753A<br>ZA0007752A<br>W09961020A1<br>W09961019A1<br>W09961013A3<br>W09961013A2<br>US20030100582A1<br>US20030004203A1<br>US20020010343A1<br>US6451829<br>US6369091<br>US6303645<br>US6271390<br>PL0345952A1<br>PL0345560A1<br>PL0345219A1<br>NZ0508413A<br>N020005889A0<br>N020005889A<br>N020005888A0<br>N020005888A<br>N020005887A0<br>N020005887A<br>JP2002516277T2<br>JP2002516276T2<br>JP2002516274T2<br>IL0139828A0<br>IL0139827A0<br>IL0139826A0<br>HU0102550AB<br>HU0102128AB<br>HU0101894AB<br>EP1079830A1<br>EP1077700A1<br>EP1077695A2<br>CZ20004351A3<br>CZ20004350A3<br>CN1317965T<br>CN1311679T<br>CN1311675T<br>CA2332999AA<br>CA2332989AA<br>CA2332985AA<br>BR9910642A<br>BR9910641A<br>BR9910640A<br>AU4312099A1<br>AU4197899A1<br>AU4094299A1<br>AU0754943B2<br>AU0754562B2 | 16.08.01<br>18.07.01<br>05.12.01<br>02.12.99<br>02.12.99<br>06.04.00<br>02.12.99<br>29.05.03<br>02.01.03<br>24.01.02<br>17.09.02<br>09.04.02<br>16.10.01<br>07.08.01<br>14.01.02<br>17.12.01<br>03.12.01<br>29.08.03<br>21.11.00<br>22.01.01<br>21.11.00<br>22.01.01<br>21.11.00<br>21.11.00<br>22.01.01<br>21.11.00<br>19.01.01<br>04.06.02<br>04.06.02<br>04.06.02<br>10.02.02<br>10.02.02<br>10.02.02<br>28.10.01<br>28.03.02<br>28.02.02<br>07.03.01<br>28.02.01<br>28.02.01<br>17.10.01<br>13.02.02<br>17.10.01<br>05.09.01<br>05.09.01<br>02.12.99<br>02.12.99<br>02.12.99<br>09.10.01<br>02.10.01<br>30.10.01<br>13.12.99<br>13.12.99<br>13.12.99<br>28.11.02<br>21.11.02 |

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**